By Josh Beckerman

Eli Lilly & Co. and Incyte Corp. have provided additional data on baricitinib that indicates the drug has a "significant effect" on recovery time for Covid-19 patients.

The companies said baricitinib in combination with remdesivir reduced recovery time and improved clinical outcomes compared with remdesivir in the ACTT-2 trial. The drug had the most impact on patients requiring oxygen.

The companies, which previously said ACTT-2 met its primary endpoint, shared additional data during a virtual conference.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

October 08, 2020 13:07 ET (17:07 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Eli Lilly Charts.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Eli Lilly Charts.